CORC

在结果中检索

CORC

浏览/检索结果: 共38条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Predicting the Molecular Models, Types, and Maturity of Kerogen in Shale Using Machine Learning and Multi-NMR Spectra 期刊论文
ENERGY & FUELS, 2022, 页码: 13
作者:  Kang, Dongliang;  Zhao, Ya-Pu
收藏  |  浏览/下载：14/0  |  提交时间：2022/08/10
A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe 期刊论文
Journal of Experimental & Clinical Cancer Research, 2020, 卷号: 39, 期号: 1
作者:  Hu,Liangning;  Li,Bo;  Chen,Gege;  Song,Dongliang;  Xu,Zhijian
收藏  |  浏览/下载：93/0  |  提交时间：2020/07/01
A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib 期刊论文
CANCER LETTERS, 2020, 卷号: 478, 页码: 45-55
作者:  Chen, Gege;  Hu, Ke;  Sun, Haiguo;  Zhou, Jinfeng;  Song, Dongliang
收藏  |  浏览/下载：91/0  |  提交时间：2020/07/01
A novel silicone derivative of natural osalmid (DCZ0858) induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma via the JAK2/STAT3 pathway 期刊论文
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 卷号: 5, 期号: 1, 页码: 11
作者:  Lu, Kang;  Li, Bo;  Zhang, Hui;  Xu, Zhijian;  Song, Dongliang
收藏  |  浏览/下载：55/0  |  提交时间：2020/07/01
Soil thermal regime alteration under experimental warming in permafrost regions of the central Tibetan Plateau 期刊论文
GEODERMA, 2020, 卷号: 372
作者:  Chen, Shengyun;  Li, Xiangfei;  Wu, Tonghua;  Xue, Kai;  Luo, Dongliang
收藏  |  浏览/下载：36/0  |  提交时间：2020/11/25
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 期刊论文
JOURNAL OF HEPATOLOGY, 2019, 卷号: 70
作者:  Gong, Guozhong;  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun
收藏  |  浏览/下载：55/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：43/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：34/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：36/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：32/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace